Keyword Analysis & Research: isis pharmaceuticals


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
isis pharmaceuticals1.010.342029020
isis1.440.32279604
pharmaceuticals1.0711335715

Keyword Research: People who searched isis pharmaceuticals also searched

Keyword CPC PCC Volume Score
isis pharmaceuticals1.30.3311956
isis pharmaceuticals wiki0.540.7684851
isis pharmaceuticals pipeline1.450.3537245
isis pharmaceuticals careers0.010.3288798
isis pharmaceuticals history0.150.8811988
isis pharmaceuticals stock0.771538989
isis pharmaceuticals address0.350.9775546
isis pharmaceuticals san diego0.05160885
isis pharmaceuticals pipeline 201610.3734887
isis pharmaceuticals pipeline 20170.690.4278790
isis pharmaceuticals clinical trials0.80.795397
isis pharmaceuticals ionis0.420.870739
isis pharmaceuticals & chemical works1.440.3175618

Search Results related to isis pharmaceuticals on Search Engine

  • Ionis Pharmaceuticals - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Ionis_Pharmaceuticals

    WebIonis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.

    DA: 80 PA: 22 MOZ Rank: 33

  • Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals

    ionispharma.com

    https://ir.ionispharma.com/news-releases/news-release-details/isis-pharmaceuticals-changes-name-ionis-pharmaceuticals

    WebIonis is focused on bringing its late-stage Phase 3 drugs, nusinersen, volanesorsen and IONIS-TTR Rx to the market and advancing its pipeline of high value drugs that have the potential to be first-in-class or best-in-class drugs to treat patients with life-threatening or serious diseases.

    DA: 47 PA: 8 MOZ Rank: 21

  • Every Moment Matters | Ionis - Ionis Pharmaceuticals

    ionispharma.com

    https://www.ionispharma.com/

    WebWe Are Transforming the Standard of Care and Pioneering New Markets. As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients.

    DA: 7 PA: 23 MOZ Rank: 2

  • About | Ionis Pharmaceuticals, Inc.

    ionispharma.com

    https://www.ionispharma.com/about/

    WebIonis: A force for life. We are guided by world-class scientists and business leaders whose drive and passion to innovate is matched only by their commitment to deliver first-in-class and best-in-class medicines to the patients who need them. View our Corporate Responsibility Report ».

    DA: 13 PA: 14 MOZ Rank: 16

  • Isis Pharmaceuticals Announces Results of Alicaforsen Phase 3 …

    ionispharma.com

    https://ir.ionispharma.com/news-releases/news-release-details/isis-pharmaceuticals-announces-results-alicaforsen-phase-3

    WebCompany to Host Webcast to Review Results of Crohn's Disease and Ulcerative Colitis Trials Today at 7:30 AM ET. CARLSBAD, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today results of two Phase 3 trials that evaluated the first-generation antisense drug alicaforsen in patients with Crohn's disease.

    DA: 5 PA: 81 MOZ Rank: 5

  • Isis Pharmaceuticals Reports Positive Data from Phase 2 Trial Of ISIS

    ionispharma.com

    https://ir.ionispharma.com/news-releases/news-release-details/isis-pharmaceuticals-reports-positive-data-phase-2-trial-isis

    WebCARLSBAD, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported data from a Phase 2 clinical trial which demonstrate that ISIS 104838, an antisense TNF-alpha inhibitor, produced a statistically significant disease response in patients with rheumatoid arthritis (RA).

    DA: 17 PA: 44 MOZ Rank: 41

  • ISIS Pharmaceuticals, Inc. Stock Nasdaq - MarketScreener.com

    marketscreener.com

    https://www.marketscreener.com/quote/stock/ISIS-PHARMACEUTICALS-INC-9734/

    WebApr 8, 2024 · Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need.

    DA: 99 PA: 45 MOZ Rank: 61

  • GSK and Isis Pharmaceuticals collaborate on RNA therapeutics …

    gsk.com

    https://www.gsk.com/en-gb/media/press-releases/gsk-and-isis-pharmaceuticals-collaborate-on-rna-therapeutics-for-rare-and-infectious-diseases/

    WebGlaxoSmithKline (GSK) and Isis Pharmaceuticals Inc. announced today a new strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious disease, including infectious diseases and some conditions causing blindness.

    DA: 78 PA: 19 MOZ Rank: 38

  • Isis Pharmaceuticals Initiates European Phase III Clinical Trial Of

    ionispharma.com

    https://ir.ionispharma.com/news-releases/news-release-details/isis-pharmaceuticals-initiates-european-phase-iii-clinical-trial

    WebCARLSBAD, Calif., June 25 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has initiated a planned second Phase III clinical trial of alicaforsen (ISIS 2302), an antisense inhibitor of Intercellular Adhesion Molecule-1 (ICAM-1), in people with active Crohn's disease. The study will be conducted in Europe ...

    DA: 62 PA: 13 MOZ Rank: 18

  • Isis Pharmaceuticals' Oral Formulation of ISIS 301012 Reduces

    ionispharma.com

    https://ir.ionispharma.com/news-releases/news-release-details/isis-pharmaceuticals-oral-formulation-isis-301012-reduces

    WebCARLSBAD, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has completed a Phase I study of an oral formulation of ISIS 301012 and has demonstrated oral bioavailability and pharmacological activity of …

    DA: 78 PA: 78 MOZ Rank: 51

  • Our Antisense Medicines | Ionis - Ionis Pharmaceuticals, Inc.

    ionispharma.com

    https://www.ionispharma.com/medicines/

    WebOur antisense therapies are designed to interact precisely with RNA, allowing us to create treatments that disrupt the disease process and change its course. With five marketed medicines and 10+ in mid- or late-stage development, our therapeutic breakthroughs are poised to continue to transform the futures of patients for years to come.

    DA: 42 PA: 45 MOZ Rank: 89

  • Genzyme and Isis Complete Licensing of Mipomersen | Ionis

    ionispharma.com

    https://ir.ionispharma.com/news-releases/news-release-details/genzyme-and-isis-complete-licensing-mipomersen

    WebJun 24, 2008 · CAMBRIDGE, Mass., and CARLSBAD, Calif., June 24 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced the finalization of the license …

    DA: 19 PA: 21 MOZ Rank: 50

  • Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals

    prnewswire.com

    https://www.prnewswire.com/news-releases/isis-pharmaceuticals-changes-name-to-ionis-pharmaceuticals-300195036.html

    WebCARLSBAD, Calif., Dec. 18, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc. Ionis (pronounced ...

    DA: 65 PA: 8 MOZ Rank: 11

  • ISIS: Ionis Pharmaceuticals Inc Stock Price Quote - - Bloomberg

    bloomberg.com

    https://www.bloomberg.com/quote/ISIS:US

    WebIonis Pharmaceuticals, Inc. operates as a biotechnology company. The Company researches in RNA-targeted drug discovery and development that focuses on drugs for patients who have unmet medical needs.

    DA: 19 PA: 48 MOZ Rank: 54

  • Antisense Technology | Ionis Pharmaceuticals, Inc.

    ionispharma.com

    https://www.ionispharma.com/ionis-technology/technology/

    WebIonis’ antisense technology. With RNA as the target that forms the basis of our novel drug discovery platform, we are tackling the most difficult to treat diseases with a focus on neurology and cardiometabolic diseases.

    DA: 17 PA: 85 MOZ Rank: 21

  • ISIS Pharmaceuticals | ISIS Stock Price, Company Overview & News - Forbes

    forbes.com

    https://www.forbes.com/companies/isis-pharmaceuticals/

    WebCarlsbad, California. About ISIS Pharmaceuticals. Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including...

    DA: 86 PA: 42 MOZ Rank: 62

  • Isis Pharmaceuticals to change its name Ionis Pharmaceuticals - CNBC

    cnbc.com

    https://www.cnbc.com/2015/12/18/isis-pharmaceuticals-to-change-its-name-ionis-pharmaceuticals.html

    WebDec 18, 2015 · Isis Pharmaceuticals on Friday announced that it will change its name to Ionis Pharmaceuticals. The company’s shares, which now trade on the Nasdaq under the ticker “ISIS,” will trade under ...

    DA: 41 PA: 89 MOZ Rank: 67

  • Home - Isispharma

    isispharma.com

    https://www.isispharma.com/en/

    WebMade in France. Isispharma is a French laboratory that formulates dermatological skincare products that are accessible and provide real results to preserve and restore your skin’s natural balance.

    DA: 4 PA: 96 MOZ Rank: 96

  • Antisense Pipeline | Ionis - Ionis Pharmaceuticals, Inc.

    ionispharma.com

    https://www.ionispharma.com/ionis-technology/antisense-pipeline/

    WebThe Ionis antisense pipeline. Our antisense technology platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 potential first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. The result of 30 years of perfecting and ...

    DA: 29 PA: 85 MOZ Rank: 75

  • Ionis Pharmaceuticals, Inc. | LinkedIn

    linkedin.com

    https://www.linkedin.com/company/ionis-pharmaceuticals

    WebIonis Pharmaceuticals, Inc. | 58,553 followers on LinkedIn. For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care.

    DA: 50 PA: 78 MOZ Rank: 48

  • Home - IonisTrials

    ionistrials.com

    https://ionistrials.com/

    WebWorking with our Community. Through our collaborations with patient advocacy organizations and communities worldwide we work to identify and understand the most urgent needs of people living with severe diseases and their caregivers. As experts in living with their disease, the patient and caregiver perspectives inform our approach to research.

    DA: 14 PA: 30 MOZ Rank: 61

  • Isis, biotech stocks move up - MarketWatch

    marketwatch.com

    https://www.marketwatch.com/story/isis-biotech-stocks-resume-gains-drug-stocks-up

    WebNEW YORK (CBS.MW) -- Biotechnology stocks resumed their recent upswing Wednesday, with shares of Isis Pharmaceuticals among the leading advancers after the company said its research collaboration ...

    DA: 46 PA: 57 MOZ Rank: 52

  • Isis Pharmaceutical changes its name to Ionis - Financial Times

    ft.com

    https://www.ft.com/content/137b6912-a5a0-11e5-97e1-a754d5d9538c

    WebDec 18, 2015 · For months it had resisted pressure to change its name, which it shares with the Islamist extremist group commonly known as Isis, but on Friday it finally rebranded as Ionis Pharmaceuticals.

    DA: 8 PA: 54 MOZ Rank: 14